Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Tri-Point Medical

This article was originally published in The Gray Sheet

Executive Summary

Tri-Point Medical: Files premarket approval application with FDA for its TraumaSeal topical tissue cohesion product. TraumaSeal is intended as an alternative to surgical sutures or staples in closing wounds "caused by skin lacerations and incisions, minimally invasive surgery, and plastic surgery," Tri-Point says. The product has been granted expedited review status by FDA. In March, the Raleigh, North Carolina firm entered an exclusive worldwide marketing agreement for the product with Johnson & Johnson's Ethicon division ("The Gray Sheet" April 1, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel